Payment overview · 2025
General Payments
$979.38
48 reported records · 17 companies
Healthcare provider profile · identity verified
Parenkumar I Patel, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WESLEY CHAPEL, FL · NPI 1760613012
Verified facts
What the public records show
CMS Open Payments records show Parenkumar I Patel, M.D. received $979.38 in general payments during 2025 across 48 reported records.
Novo Nordisk Inc accounted for 19.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $188.26 | 19.2% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $159.47 | 16.3% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $122.19 | 12.5% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $118.97 | 12.2% | 6 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $66.43 | 6.8% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $54.92 | 5.6% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $46.06 | 4.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.39 | 3.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $29.37 | 3.0% | 2 | 2025 |
| Itamar Medical Inc | Unresolved — no canonical attribution shown | $28.22 | 2.9% | 1 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $24.97 | 2.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.28 | 2.2% | 1 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $19.34 | 2.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $19.26 | 2.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.02 | 1.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.27 | 1.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.96 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $979.38 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $125.78 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $99.75 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $90.85 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $90.30 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $70.46 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $68.62 | 4 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $66.43 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $62.48 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $54.92 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $53.17 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $52.74 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $49.43 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $47.01 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $46.06 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $31.39 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $29.37 | 2 | 2025 |
Source payment records
|
|||||
| WatchPATONE Normalized: watchpatone |
Device | Itamar Medical Inc | $28.22 | 1 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $24.97 | 1 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 29 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 44 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
44 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
29 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 958 | 304 |
| Atorvastatin Calcium | Atorvastatin Calcium | 922 | 279 |
| Amlodipine Besylate | Amlodipine Besylate | 601 | 202 |
| Levothyroxine Sodium | Levothyroxine Sodium | 586 | 171 |
| Metformin Hcl | Metformin Hcl | 486 | 155 |
| Glipizide Er | Glipizide | 400 | 123 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 296 | 98 |
| Pantoprazole Sodium | Pantoprazole Sodium | 293 | 108 |
| Furosemide | Furosemide | 287 | 119 |
| Montelukast Sodium | Montelukast Sodium | 263 | 93 |
| Tamsulosin Hcl | Tamsulosin Hcl | 230 | 75 |
| Omeprazole | Omeprazole | 224 | 71 |
| Alprazolam | Alprazolam | 202 | 53 |
| Finasteride | Finasteride | 195 | 63 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 194 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 192 | 62 |
| Carvedilol | Carvedilol | 169 | 53 |
| Meloxicam | Meloxicam | 163 | 72 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 157 | 119 |
| Methylprednisolone | Methylprednisolone | 150 | 117 |
| Clopidogrel | Clopidogrel Bisulfate | 149 | 53 |
| Nifedipine Er | Nifedipine | 141 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 137 | 42 |
| Gabapentin | Gabapentin | 131 | 60 |
| Pregabalin | Pregabalin | 129 | 41 |
| Alendronate Sodium | Alendronate Sodium | 119 | 41 |
| Lisinopril | Lisinopril | 113 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 52 |
| Potassium Chloride | Potassium Chloride | 104 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | 41 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 100 | 20 |
| Dexamethasone | Dexamethasone | 98 | 67 |
| Famotidine | Famotidine | 94 | 37 |
| Simvastatin | Simvastatin | 90 | 26 |
| Fenofibrate | Fenofibrate | 88 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 37 |
| Atenolol | Atenolol | 87 | 28 |
| Tramadol Hcl | Tramadol Hcl | 86 | 48 |
| Trazodone Hcl | Trazodone Hcl | 86 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 84 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 83 | 39 |
| Memantine Hcl | Memantine Hcl | 83 | 35 |
| Baclofen | Baclofen | 77 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 77 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 75 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 24 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 68 | 37 |
| Allopurinol | Allopurinol | 62 | 23 |
| Clonazepam | Clonazepam | 61 | 17 |
| Clonidine Hcl | Clonidine Hcl | 61 | 33 |
| Hydralazine Hcl | Hydralazine Hcl | 61 | 22 |
| Benazepril Hcl | Benazepril Hcl | 57 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 54 | 47 |
| Meclizine Hcl | Meclizine Hcl | 53 | 23 |
| Prednisone | Prednisone | 50 | 32 |
| Lorazepam | Lorazepam | 49 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 43 |
| Bupropion Xl | Bupropion Hcl | 47 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | 12 |
| Celecoxib | Celecoxib | 46 | 18 |
| Farxiga | Dapagliflozin Propanediol | 44 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | 19 |
| Temazepam | Temazepam | 44 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 42 | 22 |
| Irbesartan | Irbesartan | 42 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 31 |
| Metolazone | Metolazone | 38 | 15 |
| Donepezil Hcl | Donepezil Hcl | 37 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | 13 |
| Levofloxacin | Levofloxacin | 36 | 35 |
| Oxycodone Hcl | Oxycodone Hcl | 36 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 35 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | 13 |
| Hydrocortisone | Hydrocortisone | 35 | 19 |
| Diazepam | Diazepam | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 17 |
| Ketoconazole | Ketoconazole | 33 | 18 |
| Sertraline Hcl | Sertraline Hcl | 33 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | 11 |
| Jardiance | Empagliflozin | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | 17 |
| Eliquis | Apixaban | 29 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 24 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 22 |
| Ezetimibe | Ezetimibe | 25 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Methimazole | Methimazole | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 22 | suppressed |
| Ciclopirox | Ciclopirox | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | 20 |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 16 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 16 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Sulfasalazine | Sulfasalazine | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | 12 |
| Sucralfate | Sucralfate | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $979.38 · 48 records | Novo Nordisk Inc | ABRYSVO, ACCRUFER, AIRSUPRA, AREXVY, BREZTRI, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, Kerendia, Korlym, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, Paradise Ultrasound Renal Denervation System, Rybelsus, TRELEGY ELLIPTA, VRAYLAR, Veozah, WatchPATONE, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error